Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria
- 239 Downloads
Background Underuse of medication considered beneficial is particularly common in elderly patients. A new Screening Tool to Alert Doctors to the Right Treatment (START) has been published to identify potential prescribing omissions. Objective To quantify and characterize potential prescribing omissions of cardiovascular risk management therapy using START criteria. Setting This study was conducted in the Stroke Unit of the university teaching hospital of Cova da Beira Hospital Centre, Covilhã, located in the Eastern Central Region of Portugal. Method During 6 months, the medical files of all elderly patients (age ≥ 65 years) admitted with acute cardiovascular disease were reviewed and the START criteria applied to the information of medication, at admission and at the time of discharge from the hospital Stroke Unit. Main outcome measure Potential prescribing omissions of cardiovascular and endocrine pharmacological therapy were identified and the difference in the potential prescribing omissions between admission and discharge from hospital Stroke Unit was also evaluated. Results At the time of admission to the Stroke Unit, 101 potential prescribing omissions were found in 68.1 % (n = 91) of elderly (average 1.11 omissions per patient), of which 84.2 % (n = 85) were corrected at the time of discharge. In 14 patients, 16 omissions found at admission were not corrected during hospitalization, and in 5 patients 5 new omissions were detected. Conclusion Prescribing omissions of beneficial drugs are highly prevalent in acutely ill admitted to a Stroke Unit. START criteria represent a simple, evidence-based and easy-to-use tool to screen underuse of cardiovascular risk management therapy in elderly patients.
KeywordsAdverse drug reaction Cardiovascular disease Drug prescriptions Elderly Portugal START criteria Stroke
The authors would like to acknowledge the support of Professor Miguel Castelo-Branco (MD, PhD), the Director of the Stroke Unit of Cova da Beira Hospital Centre, where the study was conducted.
The authors did not receive any financial support for the research, authorship, and/or publication of this article.
Conflicts of interest
- 2.Preventing Chronic Diseases. A Vital Investment: WHO Global Report. Geneva: World Health Organization, 2005. pp 200. CHF 30.00. ISBN 92 4 1563001. Int J Epidemiol. 2006; 35(4):1107.Google Scholar
- 3.Instituto Nacional de Estatística, Revista de Estudos Demográficos, no 46, Novembro 2009; [on-line] Available at URL: http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_publicacoes&PUBLICACOESpub_boui=81528281&PUBLICACOEStema=55466&PUBLICACOESmodo=2). Accessed on Jan 2012, ISSN 1645-5657.
- 7.Wright RM, Sloane R, Pieper CF, Ruby-Scelsi C, Twersky J, Schmader KE, Hanlon JT. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271–80.PubMedCrossRefGoogle Scholar
- 19.Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007; 28(19):2375–2414.Google Scholar
- 22.Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700–7.PubMedCrossRefGoogle Scholar
- 24.Ryan C, O’Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936–47.Google Scholar
- 28.Broeiro P, Maio I, Ramos V. Polifarmacoterapia Estratégias de Racionalização, Dossier: prescrição em medicina geral e familiar. Rev Port Clin Geral. 2008;24:625–31.Google Scholar
- 32.Smith SC, Allen J, Blair SN, Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease, 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–72.PubMedCrossRefGoogle Scholar
- 33.Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation and Prevention. Circulation. 2002;105(14):1735–43.PubMedCrossRefGoogle Scholar
- 34.Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl. 2009; 11(Suppl A):A21–A25.Google Scholar
- 35.Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107(1):149–58.PubMedCrossRefGoogle Scholar
- 36.Fox K, Garcia MA, Ardissino D, Buzzman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341–81.PubMedCrossRefGoogle Scholar
- 40.Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651–745.PubMedCrossRefGoogle Scholar
- 42.Sigal R, Malcolm J, Meggison H. Prevention of cardiovascular events in diabetes. Clin Evid. 2005;14:501–21.Google Scholar
- 43.Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.PubMedCrossRefGoogle Scholar
- 44.Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.PubMedCrossRefGoogle Scholar